BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals

Tissue Antigens

Volumn 70, Issue 6, 2007, Pages 480-486

  Sato, H ^a,b   Spagnolo, P ^b   Silveira, L ^a   Welsh, K I ^b   Du Bois, R M ^b   Newman, L S ^c   Maier, L A ^a,c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Berylliosis; BTNL2; CBD; HLA DPB1*Glu69; HLA DRB1*13; Polymorphisms

Indexed keywords

GENOMIC DNA; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; BERYLLIOSIS; BUTYROPHILIN LIKE 2 GENE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GLU69 GENE; HAPLOTYPE; HUMAN; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIZATION;

ALLELES; BERYLLIOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HLA-DP ANTIGENS; HOMOZYGOTE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 35948995030     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00944.x     Document Type: Article

References (26)

1. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991 : 88 : 54 60.
2. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996 : 104 (Suppl 5 953 6.
3. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989 : 320 : 1103 9.
4. Maier LA, McGrath DS, Sato H et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003 : 171 : 6910 8.
5. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002 : 2 : 116 26.
6. Agostini C, Trentin L, Perin A et al. Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. Am J Physiol 1999 : 277 (Pt 1 L240 50.
7. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006 : 176 : 7354 60.
8. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005 : 77 : 491 9.
9. Valentonyte R, Hampe J, Huse K et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005 : 37 : 357 64.
10. Orozco G, Eerligh P, Sanchez E et al. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum Immunol 2005 : 66 : 1235 41.
11. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005 : 171 : 54 60.
12. Maier LA, Raynolds MV, Young DA, Barker EA, Newman LS. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med 1999 : 159 (Pt 1 1342 50.
13. Bunce M, O'Neill CM, Barnardo MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995 : 46 : 355 67.
14. Welsh K, Bunce M. Molecular typing for the MHC with PCR-SSP. Rev Immunogenet 1999 : 1 : 157 76.
15. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001 : 68 : 978 89.
16. Riva A, Kohane IS. A web-based tool to retrieve human genome polymorphisms from public databases. Proc AMIA Symp 2001 : 558 62.
17. Amicosante M, Berretta F, Rossman M et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res 2005 : 6 : 94.
18. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997 : 32 : 337 40.
19. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002 : 165 : 788 94.
20. Amicosante M, Deubner D, Saltini C. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test. Sarcoidosis Vasc Diffuse Lung Dis 2005 : 22 : 175 9.
21. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993 : 262 : 242 4.
22. Wang Z, White PS, Petrovic M et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999 : 163 : 1647 53.
23. Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci U S A 2000 : 97 : 12717 22.
24. Simmonds MJ, Heward JM, Barrett JC, Franklyn JA, Gough SC. Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74. Clin Endocrinol (Oxf) 2006 : 65 : 429 32.
25. Traherne JA, Barcellos LF, Sawcer SJ et al. Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. Hum Mol Genet 2006 : 15 : 155 61.
26. Bill JR, Mack DG, Falta MT et al. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol 2005 : 175 : 7029 37.